Back to News
Market Impact: 0.3

Validea Detailed Fundamental Analysis

AMGNNDAQ
Company FundamentalsAnalyst InsightsHealthcare & BiotechCapital Returns (Dividends / Buybacks)Investor Sentiment & Positioning
Validea Detailed Fundamental Analysis

Validea's guru fundamental report rates Amgen (AMGN) at 87% using Pim van Vliet's Multi-Factor Investor model, which prioritizes low volatility, strong momentum, and high net payout yields. This score, indicating significant interest for a large-cap growth stock, stems from AMGN's strong underlying fundamentals and valuation, particularly its passing grades for market capitalization and standard deviation, despite neutral ratings for momentum and net payout yield within the strategy's criteria.

Analysis

Amgen, Inc. (AMGN) has received a favorable rating of 87% from Validea's Multi-Factor Investor model, a quantitative strategy developed by Pim van Vliet that targets low-volatility stocks with strong momentum and high net payout yields. This high score, indicating significant interest from the model, is primarily driven by AMGN's successful screening on low-risk attributes, specifically passing the criteria for market capitalization and standard deviation. However, the analysis also highlights areas of relative weakness, as the stock received a "NEUTRAL" rating on both its 'Twelve Minus One Momentum' and 'Net Payout Yield'. This suggests that while AMGN aligns with the core low-volatility tenet of the strategy, its current momentum and shareholder return profiles are not as compelling. For a large-cap growth stock in the biotechnology industry, this profile presents a classic low-risk paradox investment case, where stability is the predominant attractive factor over more aggressive growth or income metrics.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo